Overview

Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.
Phase:
Phase 2
Details
Lead Sponsor:
Reistone Biopharma Company Limited